Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: A randomized placebo-controlled study

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 8, 2013, Pages 1901-1909

  Naderer, Odin J ^a   Dumont, Etienne ^a   Zhu, John ^a   Kurtinecz, Milena ^a   Jones, Lori S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Elderly; Peptide deformylase inhibitors; Pharmacokinetics; Repeat dosing; Steady state

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; GSK 1322322; MIDAZOLAM; PEPTIDE DEFORMYLASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERTRANSAMINASEMIA; LOW DRUG DOSE; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MUSCULOSKELETAL PAIN; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION;

ELDERLY; PEPTIDE DEFORMYLASE INHIBITORS; PHARMACOKINETICS; REPEAT DOSING; STEADY-STATE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; PLACEBOS; PLASMA; YOUNG ADULT;

EID: 84880750563     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt097     Document Type: Article

References (12)

1. Schmieder R, Edwards R. Insights into antibiotic resistance through metagenomic approaches. Future Microbiol 2012; 7: 73-89.
2. Donadio S, Maffioli S, Monciardini P et al. Sources of novel antibiotics- aside the common roads. Appl Microbiol Biotechnol 2010; 88: 1261-7.
3. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010; 74: 417-33.
4. Aubart K, Benowitz A, Campobasso N et al. Hydrazinopyrimidines as a new class of peptide deformylase inhibitors. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-2110. American Society for Microbiology, Washington, DC, USA.
5. Jain R, Chen D, White RJ et al. Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr Med Chem 2005; 12: 1607-21.
6. Lewandowski T, DeMarsh P, Peters T et al. Potent activity of GSK1322322, a novel peptide deformylase inhibitor, after oral dosing in a murine multi-drug resistant Staphylococcus aureus infection. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-2113. American Society for Microbiology, Washington, DC, USA.
7. Lewandowski T, Peters T, Simon N et al. Potent activity of GSK1322322, a novel peptide deformylase inhibitor, in a Haemophilus influenzae and Streptococcus pneumoniae respiratory tract infection model. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-2115. American Society for Microbiology, Washington, DC, USA.
8. Naderer OJ, Jones LS, Zhu J et al. A novel antibacterial peptide deformylase inhibitor (GSK1322322): first time in human safety and pharmacokinetics. In: Slides presented at the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-1966. American Society for Microbiology, Washington, DC, USA.
9. Butler D, Chen D, O'Dwyer K et al. Two methodologies confirm the unique potent sub-MIC effect of peptide deformylase inhibitors on the growth of Staphylococcus aureus. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract A1-020. American Society for Microbiology, Washington, DC, USA.
10. Ross JE, Scangarella-Oman NE, Miller LA et al. Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. J Clin Microbiol 2011; 49: 3928-30.
11. Singley C, Hoover J, DeMarsh P et al. Efficacy of PDF inhibitor GSK1322322 against abscess infections caused by MRSA using a computer-controlled infusion system to recreate human PK profiles in rats. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-2114. American Society for Microbiology, Washington, DC, USA.
12. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38: 843-53.